PAEA Pediatrics End of Rotation (EOR) Practice Exam 2025 – Comprehensive All-in-One Guide for Exam Success!

Von Willebrand disease (vWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor, which plays a critical role in platelet adhesion and stabilization of factor VIII. The standard treatment for this condition focuses on increasing the levels of von Willebrand factor and factor VIII in the bloodstream.

Desmopressin is the most common treatment for mild to moderate cases of von Willebrand disease. It is a synthetic analog of vasopressin that works by stimulating the endothelial cells to release stored von Willebrand factor into the circulation. This increases the levels of both von Willebrand factor and factor VIII, thereby improving platelet function and reducing bleeding symptoms. It is especially effective in patients with type 1 vWD, which is characterized by quantitative deficiencies of von Willebrand factor.

Other treatment options, while relevant for other conditions, do not address the underlying issues faced by patients with vWD. Factor VIII concentrate is generally used for hemophilia A but is not specifically targeted at correcting vWD unless there is a significant deficiency associated. Iron supplements may be utilized to treat anemia resulting from chronic bleeding but do not directly address the clotting disorder. Platelet transfusions are typically reserved for severe cases of thrombocytopenia and do not